CVRX trades 545.2% below Wall Street's consensus target of $10.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CVRX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, CVRx, Inc. (CVRX) has a Wall Street consensus price target of $10.00, based on estimates from 7 covering analysts. With the stock currently trading at $1.55, this represents a potential upside of +545.2%. The company has a market capitalization of $41M.
Analyst price targets range from a low of $10.00 to a high of $10.00, representing a 0% spread in expectations. The median target of $10.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CVRX trades at a trailing P/E of -0.8x. Analysts expect EPS to grow -0.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LIVNLivaNova PLC | $4.1B | $75.07 | $88.50 | +17.9% | Buy | 17.2x | 15 |
 NVCRNovocure Ltd | $1.7B | $14.94 | $26.00 | +74.0% | Buy | — | 15 |
 LFSTLifeStance Health Group, Inc. | $4.6B | $11.83 | $13.86 | +17.2% | Buy | 73.7x | 11 |
 MDTMedtronic plc | $110.9B | $86.38 | $98.00 | +13.5% | Buy | 14.5x | 51 |
 ABTAbbott Laboratories | $169.8B | $97.50 | $122.00 | +25.1% | Buy | 17.7x | 41 |
 BSXBoston Scientific Corporation | $63.3B | $42.60 | $65.20 | +53.1% | Buy | 13.0x | 44 |
 AVNTAvient Corporation | $3.8B | $41.17 | $47.75 | +16.0% | Buy | 12.9x | 21 |
 ELMDElectromed, Inc. | $233M | $28.10 | $48.50 | +72.6% | Buy | 23.1x | 5 |
 SYKStryker Corporation | $105.6B | $275.43 | $370.16 | +34.4% | Buy | 18.4x | 52 |
 ZBHZimmer Biomet Holdings, Inc. | $17.1B | $88.29 | $103.11 | +16.8% | Hold | 10.3x | 42 |
Quick answers to the most common questions about buying CVRX stock.
The consensus Wall Street price target for CVRX is $10, representing 545.2% upside from the current price of $1.55. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CVRX has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $10 implies 545.2% upside from current levels.
CVRX's current price is $1.55 with a consensus target of $10 (545.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $10 for CVRX, while the most conservative target is $10. The consensus of $10 represents the median expectation. These targets typically reflect 12-month expectations.
CVRX is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CVRX stock forecast based on 7 Wall Street analysts shows a consensus price target of $10, with estimates ranging from $10 (bear case) to $10 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CVRX, with a "Buy" consensus rating and $10 price target (545.2% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CVRX analyst price targets range from $10 to $10, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.